Vorasidenib is Becoming More Accessible to Glioma Patients in the UK
Vorasidenib is a targeted drug intended for use in patients whose tumours have specific IDH1 or IDH2 mutations, which are commonly found in Grade 2 Gliomas. Recently, it’s been found [...]